🇺🇸 FDA
Pipeline program

LY3471851

17240

Phase 1 small_molecule completed

Quick answer

LY3471851 for Dermatitis, Atopic is a Phase 1 program (small_molecule) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).

Program details

Company
NEKTAR THERAPEUTICS
Indication
Dermatitis, Atopic
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials